CA-LOGITECH-G
Logitech G, a brand of Logitech (SIX: LOGN) (NASDAQ: LOGI) and leading innovator of gaming technologies and gear, announced the long awaited launch of the award-winning Logitech G CLOUD Gaming Handheld in Europe starting on 22 May 2023. In addition to North America and Taiwan, Logitech G Cloud will now be available in the United Kingdom, Germany, France, Italy, Spain, Norway, Denmark, Sweden and Finland, available on LogitechG.com, Amazon, Currys, Fnac, and MSH Electronics for a suggested retail price of $349.99 / €359 / £329.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230516005092/en/
Logitech G announced the long awaited launch of the award-winning Logitech G CLOUD Gaming Handheld in Europe starting on 22 May 2023. (Photo: Business Wire)
To celebrate the European launch, Logitech G has worked with its partners to offer a special bundle that includes up to 6 months of Xbox Game Pass Ultimate which includes Xbox Cloud Gaming, 1 month of NVIDIA GeForce NOW Priority, and 1 month of Shadow PC. It will be available in select countries effective from 22 May to 22 June 2023 while bundle supplies last.
“We’re excited to finally bring G Cloud to the European market and partner with leading retailers and partners in the region,” said Ujesh Desai, vice president and general manager at Logitech G. “G Cloud provides a fantastic new way to access and play hundreds of games, and we look forward to getting it in the hands of more players.”
In addition, Logitech G has added several new features to enhance performance based on consumer input including the following:
- Virtual button mapping—Adding the ability to map all physical controls to points on the screen, enabling players to play mobile games that do not require controller support via G CLOUD’s built-in controls.
- Analog Stick Sensitivity and Curve Customization—Increased sensitivity and customization for thumb sticks, allowing for greater control over the controller experience.
- Support for Shadow Cloud Computing* technology, allowing players to seamlessly use their G CLOUD Gaming Handheld to run a fully virtualized PC via the Shadow PC app—all from the cloud.
- Personalize Your Play With Dead Zone Customization—Leverage fully customizable joysticks and triggers (L2/R2) for the perfect balance of play.
“At Shadow, we aim to make the best of technology accessible everywhere, and on any device. Making it work on the G Cloud was an obvious and strategic choice for us,” said Jérôme Arnac, Chief Marketing and Sales Officer at Shadow. “With Shadow PC, G Cloud users will enjoy the freedom of having access to a powerful Windows PC on their handheld, with no closed games catalog, the possibility to use mods, enjoy non-gaming apps, and much more. We are incredibly excited that Logitech G brings a device to the market that supports the new ways of gaming, and we cannot wait to see how creative the community will be in using it.”
Developed in partnership with Tencent Games, the Logitech G CLOUD Gaming Handheld enables gamers to play anywhere with Wi-Fi. Key features also include:
- Remote Play, Anywhere & Anytime—Stream games from your console or PC with the Xbox app, Steam Link and other local streaming apps from Google Play Store.
- Full HD—The large 7-inch full 1080p HD touchscreen touts a 60Hz refresh rate and a full-screen 16:9 gaming experience.
- Precision Gaming Controls—Performance and feedback rival the best controllers with haptics, gyroscope, and remappable controls.
- Comfortable Play All Day—With a 12+ hour battery life and weight of only 463g, players can enjoy extended gaming sessions.
- Sustainability—All Logitech G products are certified carbon neutral, meaning that the carbon impact of the product has been reduced to zero due to Logitech’s investment in carbon offsetting and removal projects. The packaging of this product is also made from paper sourced from FSCᵀᴹ-certified forests and other controlled sources.
- Game Support—Play hundreds of Android games via Google Play for an expanded catalog of games and applications. Access the world's top titles, including Fortnite, League of Legends, Genshin Impact and more via NVIDIA GeForce NOW**; Minecraft Legends, Forza Horizon 5, Halo Infinite and others via Xbox Cloud Gaming (Beta)*** and Shadow Cloud Computing technology.
Pricing and Availability
The Logitech G CLOUD Gaming Handheld is available on LogitechG.com and at Amazon, Currys, Fnac, and MSH Electronics in May of 2023 for a suggested retail price of $349.99 / €359 / £329. For more information, please visit our website, our blog or connect with us @LogitechG.
*Shadow Cloud Computing requires an active membership. Certain restrictions apply.
**NVIDIA GeForce NOW requires an active membership and internet connection. Certain restrictions may apply.
***Xbox Cloud Gaming (Beta) requires an Xbox Game Pass Ultimate membership (sold separately) or supported free-to-play games.
About Logitech G
Logitech G, a brand of Logitech, is a global leader dedicated to serving the needs of Gamers and Creators with award-winning hardware, software and solutions. Logitech G’s industry-leading products include keyboards, mice, headsets, mousepads, simulation products such as wheels and flight sticks, webcams, lights and microphones, and specialized furniture solution; all made possible through innovative design, advanced technologies and a deep passion for gaming and creator communities.
Logitech helps all people pursue their passions and is committed to doing so in a way that is good for people and the planet. Founded in 1981 and headquartered in Lausanne, Switzerland, Logitech International is a Swiss public company listed on the SIX Swiss Exchange (LOGN) and on the Nasdaq Global Select Market (LOGI). Find Logitech G at logitechG.com, the company blog or @LogitechG.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005092/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom